drugset / Trial / NCT00042601

Evaluation of the Effect of Pramlintide on Satiety and Food Intake

NCT00042601

Phase 2 Completed 51 enrolled AstraZeneca
RandomizedCrossoverTriple-blindTreatment

Summary

This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.

Timeline

Start
2002-07
Primary completion
2003-10
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pramlintide Peptide 0.6 mg/ml Subcutaneous